Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
PEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$148.00 - $310.00
Previous CloseN/A
Volume93.15K
Average Volume (3M)546.83K
Market Cap
$10.41B
Enterprise Value$7.55B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)883.0
Beta0.92
Next Earnings
May 06, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding38,515,950
10 Day Avg. Volume563,562
30 Day Avg. Volume546,831
Standard Deviation0.14
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.94
Price to Cash Flow (P/CF)46.10
P/FCF Ratio51.00
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.06
Enterprise Value/Ebitda223.54
Forecast
1Y Price Target
$304.54Price Target Upside0.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
EarningsPEN delivered a strong Q4, with revenue of $315.5M, beating both the estimate and consensus.
Growth And InnovationUS VTE growth accelerated to 41%, showing significant momentum in this area.
Bears Say
Revenue Guidance2025 revenue guidance seems a bit soft compared to Street and buyside estimates.
---
Ownership Overview
3.44% Insiders
41.40% Mutual Funds
― Other Institutional Investors
33.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PEN FAQ
What was Penumbra’s price range in the past 12 months?
Penumbra lowest stock price was $148.00 and its highest was $310.00 in the past 12 months.
What is Penumbra’s market cap?
Penumbra’s market cap is $10.41B.
When is Penumbra’s upcoming earnings report date?
Penumbra’s upcoming earnings report date is May 06, 2025 which is in 74 days.
How were Penumbra’s earnings last quarter?
Penumbra released its earnings results on Feb 18, 2025. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.896 by $0.074.
Is Penumbra overvalued?
According to Wall Street analysts Penumbra’s price is currently Undervalued.
Does Penumbra pay dividends?
Penumbra does not currently pay dividends.
What is Penumbra’s EPS estimate?
Penumbra’s EPS estimate is 0.67.
How many shares outstanding does Penumbra have?
Penumbra has 38,515,950 shares outstanding.
What happened to Penumbra’s price movement after its last earnings report?
Penumbra reported an EPS of $0.97 in its last earnings report, beating expectations of $0.896. Following the earnings report the stock price went up 12.031%.
Which hedge fund is a major shareholder of Penumbra?
Currently, no hedge funds are holding shares in PEN
---
Penumbra Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$304.54 (0.26% Upside)
$304.54 (0.26% Upside)
Blogger Sentiment
Bullish
PEN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.1%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.27%
12-Months-Change
Fundamentals
Return on Equity
1.20%
Trailing 12-Months
Asset Growth
-1.49%
Trailing 12-Months
Company Description
Penumbra
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
---
PEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Penumbra demonstrated robust growth and profitability in its U.S. thrombectomy business, driven by product innovation and strategic expansion. However, international revenue challenges, particularly in China, and costs associated with the exit from Immersive Healthcare slightly tempered overall performance. The overall sentiment is positive due to strong domestic growth and future strategic initiatives outweighing the international setbacks.Read More>---
PEN Stock 12 Month Forecast
Average Price Target
$304.54
▲(0.26% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Smith & Nephew Snats
―
Best Analysts Covering PEN
1 Year
1 Year Success Rate
10/13 ratings generated profit
1 Year Average Return
+2.55%
reiterated a buy rating 3 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +2.55% per trade.
---